GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » E10

Summit Therapeutics (Summit Therapeutics) E10 : $-0.71 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Summit Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.71 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Summit Therapeutics was 2.40% per year. The lowest was 2.40% per year. And the median was 2.40% per year.

As of today (2024-05-18), Summit Therapeutics's current stock price is $4.44. Summit Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-0.71. Summit Therapeutics's Shiller PE Ratio of today is .


Summit Therapeutics E10 Historical Data

The historical data trend for Summit Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics E10 Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.93 -0.86 -0.93 -0.93 -0.80

Summit Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 -0.90 -0.89 -0.80 -0.71

Competitive Comparison of Summit Therapeutics's E10

For the Biotechnology subindustry, Summit Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Shiller PE Ratio falls into.



Summit Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Summit Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.06/131.7762*131.7762
=-0.060

Current CPI (Mar. 2024) = 131.7762.

Summit Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201404 -0.135 100.023 -0.178
201407 -0.135 100.520 -0.177
201410 -0.096 100.176 -0.126
201501 -0.105 98.604 -0.140
201504 -0.093 99.824 -0.123
201507 -0.109 100.691 -0.143
201510 -0.139 100.346 -0.183
201601 -0.114 99.957 -0.150
201604 -0.132 100.947 -0.172
201607 -0.691 101.524 -0.897
201610 -0.098 101.988 -0.127
201701 -0.100 102.456 -0.129
201704 -0.103 103.167 -0.132
201707 -0.066 103.278 -0.084
201710 -0.013 104.070 -0.016
201801 -0.226 104.578 -0.285
201804 -0.110 105.708 -0.137
201807 0.420 106.324 0.521
201810 -0.127 106.695 -0.157
201901 -0.066 106.200 -0.082
201904 -0.039 107.818 -0.048
201907 -0.036 108.250 -0.044
201910 -0.052 108.577 -0.063
202003 -0.091 108.902 -0.110
202006 -0.230 108.767 -0.279
202009 -0.260 109.815 -0.312
202012 -0.180 109.897 -0.216
202103 -0.210 111.754 -0.248
202106 -0.270 114.631 -0.310
202109 -0.200 115.734 -0.228
202112 -0.280 117.630 -0.314
202203 -0.150 121.301 -0.163
202206 -0.120 125.017 -0.126
202209 -0.100 125.227 -0.105
202212 -0.040 125.222 -0.042
202303 -1.430 127.348 -1.480
202306 -0.020 128.729 -0.020
202309 -0.030 129.860 -0.030
202312 -0.010 129.419 -0.010
202403 -0.060 131.776 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.


Summit Therapeutics  (NAS:SMMT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Summit Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (Summit Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Summit Therapeutics (Summit Therapeutics) Headlines

From GuruFocus

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

By Business Wire Business Wire 03-03-2023